Compare CGBD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | ORIC |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 837.3M |
| IPO Year | N/A | 2020 |
| Metric | CGBD | ORIC |
|---|---|---|
| Price | $11.60 | $8.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $12.92 | ★ $19.73 |
| AVG Volume (30 Days) | 720.8K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $4.65 |
| 52 Week High | $14.48 | $14.93 |
| Indicator | CGBD | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 36.43 |
| Support Level | $11.19 | $7.90 |
| Resistance Level | $13.06 | $11.22 |
| Average True Range (ATR) | 0.29 | 0.55 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 36.45 | 6.47 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.